TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, has been invited by MasterLink Securities to hold an investor conference on December 6, 2019.
December 3, 2019
· 1 min read